Lumos Pharma Inc expected to post a loss of $1.10 a share - Earnings Preview

Lumos Pharma

08/08/2023 24:02

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a
rise
in quarterly revenue when it reports  results on August 9. 
    * The Austin Texas-based  company is expected to report  a
3.0% increase in revenue to $415.17 thousand from $403 thousand
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Lumos Pharma Inc is
for a
loss of $1.10 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $19​, above​ its last closing price of $3.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.11       -1.12      -0.89     Beat    20.8
 Dec. 31 2023  -0.91       -0.93      -0.99     Missed  -6.3
 Sep. 30 2022  -1.00       -1.01      -0.86     Beat    14.7​
 Jun. 30 2022  -0.98       -0.99      -0.94     Beat    4.6
 ​​Mar.        -0.89       -0.89      -0.92     Missed  -3.1
 31 2022                                                
 Dec. 31 2021              -0.92      -0.67     Beat    27​
 Sep. 30 2021  -1.07       -1.07      -0.90     Beat    16
 Jun. 30 2021  -1.05       -1.03      -1.04     Missed  -0.6
 This summary was machine generated August 7 at 23:02 GMT.  All
figures in US dollars  unless otherwise stated